Alzamend Accounts Payable vs Total Liab Analysis

ALZN Stock

USD 1.27 0.01 0.79%

Alzamend Neuro financial indicator trend analysis is way more than just evaluating Alzamend Neuro prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alzamend Neuro is a good investment. Please check the relationship between Alzamend Neuro Accounts Payable and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alzamend Neuro Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Alzamend Neuro's Accounts Payable and Total Liab is 0.85. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Alzamend Neuro, assuming nothing else is changed. The correlation between historical values of Alzamend Neuro's Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Alzamend Neuro are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Alzamend Neuro's Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.85

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Alzamend Neuro obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Alzamend Neuro are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Alzamend Neuro's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alzamend Neuro current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.At this time, Alzamend Neuro's Selling General Administrative is very stable compared to the past year. As of the 7th of January 2025, Issuance Of Capital Stock is likely to grow to about 5.7 M, though Enterprise Value Over EBITDA is likely to grow to (0.52).

Alzamend Neuro fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Deferred Long Term Liab	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt
Total Current Liabilities		0.32	-0.94	0.98	-0.27	-0.72	0.02	-0.36	-0.06	0.69	0.98	-0.31	-0.74	-0.04	0.07	0.07	0.84	-0.77	-0.96	-0.84	0.81	0.86	-0.29	-0.68	-0.33	0.69
Net Tangible Assets	0.32		-0.55	0.42	-0.01	-0.17	0.9	0.39	0.85	0.66	0.24	0.72	-0.69	-0.89	0.9	0.9	0.67	-0.68	-0.23	-0.62	0.73	0.23	0.74	0.09	0.71	0.66
Retained Earnings	-0.94	-0.55		-0.96	0.21	0.55	-0.28	0.15	-0.19	-0.85	-0.91	0.07	0.89	0.28	-0.32	-0.32	-0.93	0.9	0.93	0.9	-0.93	-0.85	0.04	0.53	0.09	-0.85
Accounts Payable	0.98	0.42	-0.96		-0.14	-0.67	0.14	-0.23	0.04	0.72	0.96	-0.22	-0.77	-0.13	0.16	0.16	0.87	-0.8	-0.95	-0.83	0.86	0.85	-0.19	-0.6	-0.24	0.72
Net Receivables	-0.27	-0.01	0.21	-0.14		0.14	0.04	0.25	-0.11	-0.29	-0.22	-0.04	0.3	0.14	-0.15	-0.15	-0.25	0.3	0.22	0.32	-0.26	-0.21	-0.05	0.11	-0.04	-0.29
Deferred Long Term Liab	-0.72	-0.17	0.55	-0.67	0.14		0.14	0.51	0.2	-0.3	-0.71	0.37	0.39	-0.13	0.1	0.1	-0.43	0.46	0.61	0.61	-0.4	-0.38	0.35	0.69	0.39	-0.3
Total Current Assets	0.02	0.9	-0.28	0.14	0.04	0.14		0.73	0.98	0.49	-0.06	0.92	-0.51	-0.98	0.98	0.98	0.43	-0.47	0.03	-0.3	0.55	-0.03	0.93	0.5	0.92	0.49
Common Stock	-0.36	0.39	0.15	-0.23	0.25	0.51	0.73		0.71	0.11	-0.42	0.78	-0.1	-0.66	0.65	0.65	-0.06	-0.05	0.31	0.27	0.11	-0.35	0.78	0.88	0.79	0.11
Total Assets	-0.06	0.85	-0.19	0.04	-0.11	0.2	0.98	0.71		0.41	-0.14	0.96	-0.43	-0.99	0.99	0.99	0.36	-0.39	0.13	-0.23	0.48	-0.1	0.97	0.56	0.96	0.41
Short Long Term Debt Total	0.69	0.66	-0.85	0.72	-0.29	-0.3	0.49	0.11	0.41		0.65	0.21	-0.98	-0.49	0.52	0.52	0.87	-0.97	-0.71	-0.87	0.9	0.66	0.25	-0.25	0.2	1.0
Other Current Liab	0.98	0.24	-0.91	0.96	-0.22	-0.71	-0.06	-0.42	-0.14	0.65		-0.4	-0.7	0.05	-0.02	-0.02	0.82	-0.73	-0.98	-0.81	0.77	0.89	-0.38	-0.7	-0.42	0.65
Total Stockholder Equity	-0.31	0.72	0.07	-0.22	-0.04	0.37	0.92	0.78	0.96	0.21	-0.4		-0.22	-0.93	0.92	0.92	0.11	-0.18	0.38	0.0	0.24	-0.34	1.0	0.72	1.0	0.21
Current Deferred Revenue	-0.74	-0.69	0.89	-0.77	0.3	0.39	-0.51	-0.1	-0.43	-0.98	-0.7	-0.22		0.51	-0.54	-0.54	-0.86	1.0	0.75	0.9	-0.92	-0.63	-0.25	0.27	-0.2	-0.98
Net Debt	-0.04	-0.89	0.28	-0.13	0.14	-0.13	-0.98	-0.66	-0.99	-0.49	0.05	-0.93	0.51		-1.0	-1.0	-0.45	0.48	-0.03	0.33	-0.56	0.01	-0.94	-0.49	-0.92	-0.49
Cash	0.07	0.9	-0.32	0.16	-0.15	0.1	0.98	0.65	0.99	0.52	-0.02	0.92	-0.54	-1.0		1.0	0.47	-0.51	0.0	-0.36	0.59	0.02	0.93	0.46	0.91	0.52
Cash And Short Term Investments	0.07	0.9	-0.32	0.16	-0.15	0.1	0.98	0.65	0.99	0.52	-0.02	0.92	-0.54	-1.0	1.0		0.47	-0.51	0.0	-0.36	0.59	0.02	0.93	0.46	0.91	0.52
Common Stock Total Equity	0.84	0.67	-0.93	0.87	-0.25	-0.43	0.43	-0.06	0.36	0.87	0.82	0.11	-0.86	-0.45	0.47	0.47		-0.86	-0.81	-0.87	0.97	0.86	0.14	-0.4	0.09	0.87
Common Stock Shares Outstanding	-0.77	-0.68	0.9	-0.8	0.3	0.46	-0.47	-0.05	-0.39	-0.97	-0.73	-0.18	1.0	0.48	-0.51	-0.51	-0.86		0.77	0.92	-0.91	-0.64	-0.21	0.32	-0.16	-0.97
Non Current Liabilities Total	-0.96	-0.23	0.93	-0.95	0.22	0.61	0.03	0.31	0.13	-0.71	-0.98	0.38	0.75	-0.03	0.0	0.0	-0.81	0.77		0.78	-0.79	-0.89	0.35	0.62	0.39	-0.71
Other Current Assets	-0.84	-0.62	0.9	-0.83	0.32	0.61	-0.3	0.27	-0.23	-0.87	-0.81	0.0	0.9	0.33	-0.36	-0.36	-0.87	0.92	0.78		-0.85	-0.72	-0.03	0.59	0.02	-0.87
Other Stockholder Equity	0.81	0.73	-0.93	0.86	-0.26	-0.4	0.55	0.11	0.48	0.9	0.77	0.24	-0.92	-0.56	0.59	0.59	0.97	-0.91	-0.79	-0.85		0.77	0.26	-0.25	0.22	0.9
Total Liab	0.86	0.23	-0.85	0.85	-0.21	-0.38	-0.03	-0.35	-0.1	0.66	0.89	-0.34	-0.63	0.01	0.02	0.02	0.86	-0.64	-0.89	-0.72	0.77		-0.32	-0.59	-0.35	0.66
Net Invested Capital	-0.29	0.74	0.04	-0.19	-0.05	0.35	0.93	0.78	0.97	0.25	-0.38	1.0	-0.25	-0.94	0.93	0.93	0.14	-0.21	0.35	-0.03	0.26	-0.32		0.7	1.0	0.25
Capital Stock	-0.68	0.09	0.53	-0.6	0.11	0.69	0.5	0.88	0.56	-0.25	-0.7	0.72	0.27	-0.49	0.46	0.46	-0.4	0.32	0.62	0.59	-0.25	-0.59	0.7		0.73	-0.25
Net Working Capital	-0.33	0.71	0.09	-0.24	-0.04	0.39	0.92	0.79	0.96	0.2	-0.42	1.0	-0.2	-0.92	0.91	0.91	0.09	-0.16	0.39	0.02	0.22	-0.35	1.0	0.73		0.2
Short Term Debt	0.69	0.66	-0.85	0.72	-0.29	-0.3	0.49	0.11	0.41	1.0	0.65	0.21	-0.98	-0.49	0.52	0.52	0.87	-0.97	-0.71	-0.87	0.9	0.66	0.25	-0.25	0.2

Click cells to compare fundamentals

Alzamend Neuro Account Relationship Matchups

Alzamend Neuro fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	899.6K	1.2M	2.9M	3.2M	3.7M	3.9M
Net Tangible Assets	821.6K	2.0M	13.4M	3.0M	3.5M	3.3M
Retained Earnings	(16.8M)	(29.2M)	(44.1M)	(54.0M)	(48.6M)	(46.2M)
Accounts Payable	503.6K	1.2M	2.9M	2.9M	3.4M	3.5M
Total Current Assets	2.9M	14.4M	5.8M	455.2K	523.5K	497.4K
Common Stock	6.7K	9.5K	9.7K	69.0	79.35	75.38
Total Assets	2.9M	14.5M	5.9M	631.6K	726.3K	690.0K
Other Current Liab	60.7K	2.1K	2.9M	3.2M	3.7M	3.9M
Total Stockholder Equity	2.0M	13.4M	3.0M	(2.6M)	(3.0M)	(2.8M)
Net Debt	(1.6M)	(14.1M)	(5.1M)	(75.3K)	(67.8K)	(71.2K)
Cash	1.9M	14.1M	5.1M	376.0K	432.5K	410.8K
Non Current Assets Total	352.5K	102.9K	79.8K	176.3K	202.8K	130.5K
Cash And Short Term Investments	1.9M	14.1M	5.1M	376.0K	432.5K	410.8K
Common Stock Total Equity	6.5K	6.7K	9.5K	9.7K	11.1K	8.5K
Common Stock Shares Outstanding	484.3K	594.0K	650.1K	676.6K	608.9K	578.5K
Liabilities And Stockholders Equity	2.9M	14.5M	5.9M	631.6K	726.3K	690.0K
Other Current Assets	614.6K	349.7K	694.9K	79.2K	71.3K	67.7K
Other Stockholder Equity	33.7M	57.4M	62.0M	51.4M	59.1M	46.7M
Total Liab	899.6K	1.2M	2.9M	3.2M	3.7M	1.9M
Net Invested Capital	2.3M	13.4M	3.0M	(2.3M)	(2.6M)	(2.5M)
Capital Stock	6.8K	9.5K	9.7K	69.0	62.1	59.0
Net Working Capital	2.0M	13.2M	3.0M	(2.8M)	(3.2M)	(3.0M)

When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:

How To Invest In Alzamend

Details

Is Alzamend Stock a good investment?

Details

What is Alzamend Neuro's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(138.31)

Return On Assets

(2.14)

Return On Equity

(44.08)

The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alzamend Accounts Payable vs Total Liab Analysis

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Liab

Alzamend Neuro fundamental ratios Correlations

Alzamend Neuro Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alzamend Neuro fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Common Stock Shares Outstanding	+ 1.0	Current Deferred Revenue
Cash And Short Term Investments	+ 1.0	Cash
Net Working Capital	+ 1.0	Net Invested Capital

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Assets
Short Term Debt	- 0.98	Current Deferred Revenue
Non Current Liabilities Total	- 0.98	Other Current Liab
Current Deferred Revenue	- 0.98	Short Long Term Debt Total